Ondine Biopharma AIM Notification


 
TIDMOBP 
 
Ondine Biopharma AIM Notification 
FOR:  ONDINE BIOPHARMA CORPORATION 
 
TSX, AIM SYMBOL:  OBP 
 
April 14, 2010 
 
Ondine Biopharma AIM Notification 
 
VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 14, 2010) - Ondine Biopharma Corporation (TSX:OBP)(AIM:OBP) ("Ondine" or the "Company") today announces the following transactions by a Director of the Company, and the combined ownership by the Director, the Director's family, and by a charitable foundation of which the Director and the Director's spouse are directors: 
 
/T/ 
 
Name                                                           Carolyn Cross 
Relationship to the Company                                        Director, 
                                                            Chairman and CEO 
Date the transaction was reported to the Company              April 13, 2010 
Date of trade                                                 April 13, 2010 
Nature of the transaction                                        Exercise of 
                                                                    Warrants 
Type of security acquired                                      Common shares 
Number of securities acquired                                      1,500,000 
Price per security                                                Cdn. $0.05 
Nature and extent of the above's interest in the transaction     100% direct 
                                                                   ownership 
                                                                    interest 
Number of shares held in the Company by the Director               9,607,510 
immediately subsequent to completion of the transaction 
Percentage direct ownership in the Company of the Director             7.65% 
immediately subsequent to completion of the transaction 
Number of shares held in the Company by the Director and          21,221,133 
Director's family immediately subsequent to completion of 
the transaction, together with the shares held by the 
Courthill Foundation 
Percentage ownership in the Company by the Director and               16.91% 
Director's family immediately subsequent to completion of 
the transaction, together with the holdings of the Courthill 
Foundation (19.74% assuming all options and warrants held by 
the director are exercised) 
Close period                                                              No 
Other                                                          The 1,500,000 
                                                             shares acquired 
                                                                on April 13, 
                                                            2010 are subject 
                                                             to a regulatory 
                                                              hold period in 
                                                             Canada expiring 
                                                              April 24, 2010 
 
/T/ 
 
 
-30- 
 
FOR FURTHER INFORMATION PLEASE CONTACT: 
 
Ondine Biopharma Corporation 
Carolyn Cross 
Chairman and Chief Executive Officer 
(604) 669-0555 
ccross@ondinebiopharma.com 
 
OR 
 
Canaccord Adams Ltd. 
Ryan Gaffney 
Nominated Adviser 
+4420 7050 6500 
 
 
Ondine Biopharma Corporation

Ondine Biomed (LSE:OBP)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024